UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13G
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

                            CORCEPT THERAPEUTICS INC
--------------------------------------------------------------------------------
                                (Name of Issuer)

                         COMMON STOCK, $0.001 PAR VALUE
--------------------------------------------------------------------------------
                         (Title of Class of Securities)

                                   218352102
          ------------------------------------------------------------
                                 (CUSIP Number)

                               DECEMBER 31, 2005
          ------------------------------------------------------------
            (Date of Event which Requires Filing of this Statement)

CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE
IS FILED:

[ ] RULE 13d-1(b)

[X] RULE 13d-1(c)

[ ] RULE 13d-1(d)

*THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON'S
INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND
FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER
DISCLOSURES PROVIDED IN A PRIOR COVER PAGE.

THE INFORMATION REQUIRED ON THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED
TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF
1934 (THE "ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE
ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE
NOTES).



                               Page 1 of 5 Pages


CUSIP No.  218352102
           ---------

--------------------------------------------------------------------------------
1  NAMES OF REPORTING PERSONS
   I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

   Joseph L. Dowling, III
--------------------------------------------------------------------------------
2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)   (A) [ ]
                                                                         (B) [X]
--------------------------------------------------------------------------------
3  SEC USE ONLY

--------------------------------------------------------------------------------
4  CITIZENSHIP OR PLACE OF ORGANIZATION

   United States
--------------------------------------------------------------------------------
                        5  SOLE VOTING POWER
 NUMBER OF                 643,339
   SHARES               --------------------------------------------------------
BENEFICIALLY            6  SHARED VOTING POWER
  OWNED BY                 -0-
   EACH                 --------------------------------------------------------
 REPORTING              7  SOLE DISPOSITIVE POWER
  PERSON                   643,339
   WITH                 --------------------------------------------------------
                        8  SHARED DISPOSITIVE POWER
                           -0-
--------------------------------------------------------------------------------
9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   643,339
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      [ ]
   (SEE INSTRUCTIONS)

--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   2.8%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     IN

--------------------------------------------------------------------------------

                               Page 2 of 5 Pages


ITEM 1(a)       NAME OF ISSUER:

                Corcept Therapeutics Inc

ITEM 1(b)       ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

                275 Middlefield Road, Suite A
                Menlo Park, CA 94025.

ITEM 2(a)       NAME OF PERSON FILING:

                Joseph L. Dowling, III

ITEM 2(b)       ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

                540 Madison Avenue, 38th Floor
                New York, New York  10022

ITEM 2(c)       CITIZENSHIP:

                United States

ITEM 2(d)       TITLE OF CLASS OF SECURITIES:

                Common Stock, par value $0.01 per share

ITEM 2(e)       CUSIP NUMBER:

                218352102

ITEM 3.         IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(b) OR
                (c), CHECK WHETHER THE PERSON FILING IS A:   N/A

     (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C.
78o).

     (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15
U.S.C. 78c).

     (d) [ ] Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).

     (e) [ ] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);

     (f) [ ] An employee benefit plan or endowment fund in accordance with
ss.240.13d-1(b)(1)(ii)(F);

                               Page 3 of 5 Pages



     (g) [ ] A parent holding company or control person in accordance with
ss.240.13d 1(b)(1)(ii)(G);

     (h) [ ] A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);

     (i) [ ] A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a 3);

     (j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

ITEM 4.         OWNERSHIP.

     Set forth in the table below is the aggregate number of shares of Common
Stock beneficially owned as of the date hereof by each of the following,
together with the percentage of outstanding shares of Common Stock that such
ownership represents based upon 22,704,000 shares of Common Stock outstanding on
December 31, 2005.

                                                            Percent of
                                         Number of            Class
                Name                      Shares           Outstanding
     ---------------------------        ----------         -----------
     Narragansett I, L.P.                 270,203             1.2%
     Narragansett Offshore, Ltd.          373,136             1.6%
                                        ---------           ------
     Total:                               643,339             2.8%

     By virtue of his status as the sole managing member of entities that have
the power to control the investment decisions of Narragansett I, L.P. and
Narragansett Offshore, Ltd., Joseph L. Dowling, III, may be deemed to be the
beneficial owner of shares owned by Narragansett I, L.P. and Narragansett
Offshore, Ltd., and may be deemed to have sole power to vote or direct the vote
of and sole power to dispose or direct the disposition of such securities.


ITEM 5.         OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [ X ].

     ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

             N/A

     ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
             THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR
             CONTROL PERSON.

             N/A

     ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

             N/A

     ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

             N/A

     ITEM 10. CERTIFICATION.

     By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.

                               Page 4 of 5 Pages


                                   SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I
hereby certify that the information set forth in this statement is true,
complete and correct.

February 14, 2006

                                        /s/ Joseph L. Dowling, III
                                        -----------------------------
                                            Joseph L. Dowling, III